It operates in the world of health and science. Now — the numbers.
An investor who bought at the very peak is down 78% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.
The stock sits at $0.13. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
On our five-subject report card, NMNSF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: NMNSF is a high-risk stock — not yet profitable, and its future rides on its product catching on.